Kopsky David J, Vrancken Alexander F J E, Keppel Hesselink Jan M, van Eijk Ruben P A, Notermans Nicolette C
Institute for Neuropathic Pain, Amsterdam, the Netherlands.
Department of Neurology, Brain Centre University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
J Pain Res. 2020 May 1;13:877-882. doi: 10.2147/JPR.S243434. eCollection 2020.
Topical analgesics are an upcoming treatment option for neuropathic pain. In this observational study, we performed a double-blind placebo-controlled response test (DOBRET) in patients with polyneuropathy to determine the personalized analgesic effect of phenytoin 10% cream.
In a double-blind fashion, 12 consecutive adult patients with symmetrical painful polyneuropathy and equal pain intensity of ≥4 on the 11-point numerical rating scale (NRS) applied phenytoin10% cream on one painful area and a placebo cream on the corresponding contralateral area. We defined responders as patients who experienced a pain reduction ≥2 NRS points from baseline and ≥1 NRS point difference in pain reduction in favour of phenytoin 10% cream compared with placebo cream within 30 minutes after application. We also evaluated the percentage of pain reduction and frequency of 30% and 50% pain relief from baseline.
Six patients (50%) were responders. Compared with placebo cream, pain reduction was higher in phenytoin 10% cream-applied areas with mean difference in pain reduction of 1.3 (95% CI: 1.1 to 1.8; p<0.001) on the NRS and mean percentage difference in pain reduction of 22% (95% CI: 13% to 32%; p =0.03). All responders had at least 30% pain reduction, and 4 out of 6 had at least 50% pain reduction in the phenytoin 10% cream applied area. All non-responders had less than 30% pain reduction. No side effects were reported.
A DOBRET is easy to perform, quickly identifies an analgesic effect in responders and could be a useful tool to personalize neuropathic pain treatment with topical formulations.
局部用镇痛药是一种新兴的神经性疼痛治疗选择。在这项观察性研究中,我们对患有多发性神经病的患者进行了双盲安慰剂对照反应试验(DOBRET),以确定10%苯妥英乳膏的个性化镇痛效果。
以双盲方式,12例连续的成年对称性疼痛性多发性神经病患者,且在11点数字评定量表(NRS)上疼痛强度均≥4,在一个疼痛区域涂抹10%苯妥英乳膏,在相应的对侧区域涂抹安慰剂乳膏。我们将反应者定义为在用药后30分钟内疼痛较基线降低≥2个NRS点,且与安慰剂乳膏相比,使用10%苯妥英乳膏后疼痛降低差值≥1个NRS点的患者。我们还评估了疼痛降低的百分比以及与基线相比疼痛缓解30%和50%的频率。
6例患者(50%)为反应者。与安慰剂乳膏相比,涂抹10%苯妥英乳膏的区域疼痛降低更明显,NRS上疼痛降低的平均差值为1.3(95%CI:1.1至1.8;p<0.001),疼痛降低的平均百分比差值为22%(95%CI:13%至32%;p =0.03)。所有反应者在涂抹10%苯妥英乳膏的区域疼痛至少降低30%,6例中有4例疼痛至少降低50%。所有无反应者疼痛降低均少于30%。未报告有副作用。
DOBRET易于实施,能快速识别反应者的镇痛效果,可能是一种利用局部制剂实现神经性疼痛个性化治疗的有用工具。